Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

12-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease.

Next Previous
Trial Profile

12-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 31 May 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mavoglurant (Primary)
  • Indications Drug-induced dyskinesia; Parkinson's disease
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Sponsors Novartis

Most Recent Events

  • 23 May 2016 Primary endpoint has not been met. (Abnormal Involuntary Movement Scale), as per an article published in the Movement Disorders.
  • 23 May 2016 Results published in the Movement Disorders
  • 07 Sep 2012 Planned End Date changed from 1 Jun 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top